Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563522 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers
A Phase 3 study, sponsored by Helixmith Co..
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT02563522: Clinical Trial Phase 3 study, sponsored by Helixmith Co..
NCT02563522 is a Phase 3 study that was terminated before completion, run by Helixmith Co.. The registered enrollment target is 44 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02563522, a Phase 3 study, was terminated before completion, sponsored by Helixmith Co..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers.
Primary Outcome
Determine the proportion of subjects with a target Wound Closure from baseline to month 4 visit
Interventions
- DRUG Placebo
- GENETIC Engensis (VM202)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 3 |
Why NCT02563522 stopped before completion
NCT02563522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02563522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02563522 about?
NCT02563522 is a clinical study titled "Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers". This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers.
What is the current status of trial NCT02563522?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2017-06-27. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT02563522?
The interventions under investigation include: Placebo (DRUG), Engensis (VM202) (GENETIC).
Who is sponsoring clinical trial NCT02563522?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02563522's enrollment target sits among peer trials
44 1874th of 2000 higher than 125 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI